Taiho Pharmaceutical Company Limited

Tomonobu Mutsumi

Hideki Kazuno

Crystal Form I of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting powder X-ray peaks at two or more angles selected from the group consisting of 11.6&#xb0;, 17.2&#xb0;, 17.8&#xb0;, 23.3&#xb0;, 27.1&#xb0;, and 29.3&#xb0; as a diffraction angle (2&#x3b8;&#xb1;0.2&#xb0;).

Stable crystal form of tipiracil hydrochloride and crystallization method for the same

An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4 (1H,3H)-pyrimidinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4 (1H,3H)-pyrimidinedione hydrochloride exhibiting characteristic peaks at angles of 11.6&#xb0;, 17.2&#xb0;, 17.8&#xb0;, 23.3&#xb0;, 27.1&#xb0;, and 29.3&#xb0; as a diffraction angle (2&#x3b8;&#xb1;0.1&#xb0;) in powder X-ray diffraction.

An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting characteristic peaks at angles of 11.6&#xb0;, 17.2&#xb0;, 17.8&#xb0;, 23.3&#xb0;, 27.1&#xb0;, and 29.3&#xb0; as a diffraction angle (2&#x3b8;&#xb1;0.1&#xb0;) in powder X-ray diffraction.

Growing community of inventors

Saitama, Japan

Tomonobu Mutsumi